Biondvax Pharmaceuticals Stock EBITDA
BVXVDelisted Stock | USD 1.35 0.03 2.17% |
BiondVax Pharmaceuticals fundamentals help investors to digest information that contributes to BiondVax Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of BiondVax Stock. The fundamental analysis module provides a way to measure BiondVax Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to BiondVax Pharmaceuticals stock.
BiondVax |
BiondVax Pharmaceuticals Company EBITDA Analysis
BiondVax Pharmaceuticals' EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.
Current BiondVax Pharmaceuticals EBITDA | (10.5 M) |
Most of BiondVax Pharmaceuticals' fundamental indicators, such as EBITDA, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, BiondVax Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.
CompetitionAccording to the company disclosure, BiondVax Pharmaceuticals reported earnings before interest,tax, depreciation and amortization of (10.5 Million). This is 101.2% lower than that of the Pharmaceuticals sector and 110.48% lower than that of the Health Care industry. The ebitda for all United States stocks is 100.27% higher than that of the company.
BiondVax EBITDA Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses BiondVax Pharmaceuticals' direct or indirect competition against its EBITDA to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of BiondVax Pharmaceuticals could also be used in its relative valuation, which is a method of valuing BiondVax Pharmaceuticals by comparing valuation metrics of similar companies.BiondVax Pharmaceuticals is currently under evaluation in ebitda category among its peers.
BiondVax Fundamentals
Return On Equity | -56.02 | |||
Return On Asset | -0.31 | |||
Current Valuation | 21.94 M | |||
Shares Outstanding | 3.65 M | |||
Shares Owned By Insiders | 20.01 % | |||
Shares Owned By Institutions | 10.69 % | |||
Number Of Shares Shorted | 4.88 K | |||
Price To Earning | (4.91) X | |||
Price To Book | 7.48 X | |||
EBITDA | (10.5 M) | |||
Net Income | (5.8 M) | |||
Cash And Equivalents | 14.55 M | |||
Cash Per Share | 2.23 X | |||
Total Debt | 21.54 M | |||
Current Ratio | 1.71 X | |||
Book Value Per Share | (1.96) X | |||
Cash Flow From Operations | (7.26 M) | |||
Short Ratio | 0.32 X | |||
Earnings Per Share | (2.35) X | |||
Target Price | 39.0 | |||
Number Of Employees | 33 | |||
Beta | 2.37 | |||
Market Capitalization | 4.97 M | |||
Total Asset | 27.07 M | |||
Retained Earnings | (115.83 M) | |||
Working Capital | 12.03 M | |||
Current Asset | 36.93 M | |||
Current Liabilities | 1.7 M | |||
Z Score | -6.6 | |||
Net Asset | 27.07 M |
About BiondVax Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze BiondVax Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of BiondVax Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of BiondVax Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in interest. You can also try the AI Portfolio Architect module to use AI to generate optimal portfolios and find profitable investment opportunities.
Other Consideration for investing in BiondVax Stock
If you are still planning to invest in BiondVax Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the BiondVax Pharmaceuticals' history and understand the potential risks before investing.
Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
Share Portfolio Track or share privately all of your investments from the convenience of any device | |
USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios |